Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 1

Status

Recruiting 5Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER_GOV 1OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 2

Conditions

Colorectal Neoplasms 45Stomach Neoplasms 20Pancreatic Neoplasms 20Rectal Neoplasms 16Adenocarcinoma Of Esophagus 14Esophageal Neoplasms 13Colonic Neoplasms 12Neoplasms 11Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 11Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Ovarian Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lung Neoplasms 4Gastrointestinal Neoplasms 4Endometrial Neoplasms 4Carcinoma 4Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Biliary Tract Neoplasms 3Advanced Solid Tumors 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2

Interventions

Oxaliplatin 9Capecitabine 9Fluorouracil 7pembrolizumab 6Paclitaxel 6Leucovorin 6Cisplatin 5zolbetuximab 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Gemcitabine 3Docetaxel 3fludarabine 2darolutamide 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Nivolumab 2Irinotecan 2Cyclophosphamide 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Adenocarcinoma × Fluorouracil × 90 days × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04864067 2026-05-08

NOAHS-ARC

Servicio de Salud Metropolitano Sur Oriente

Phase 2 Completed
39 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT03504397 2026-05-04

Spotlight

Astellas Pharma Inc

Phase 3 Active not recruiting
565 enrolled 63 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06846346 2026-04-28

GRACIE

UNICANCER

Phase 2 Recruiting
88 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡